Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1005764

registered interest
date	12/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the effectiveness of NHS and medical professional body guidelines on the prescription of medicinal cannabis in ensuring the eligibility for prescription of patients for whom that treatment might be advantageous.
tabling member constituency	Birkenhead
tabling member printed	Frank Field
uin	190361
answer	answer is ministerial correction date of answer 15/11/2018 answer text <p>The Medical Director of NHS England, Professor Steve Powis, and the Chief Medical Officer, Professor Dame Sally Davies, have written to relevant clinicians to coincide with the coming into force of the rescheduling of cannabis-based medicinal products. The guidance in this letter, which signposts interim clinical advice commissioned from the British Paediatric Neurology Association and the Royal College of Physicians, is in line with normal clinical practice. The decision to prescribe cannabis-based products for medicinal use will be made on a case-by-case basis, based on clinical need and in-line with existing governance procedures for prescribing unlicensed medicines.</p><p> </p><p>The Department has commissioned the National Institute for Health and Care Excellence to produce clinical guidance by October 2019, which will update and replace the interim advice.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 15/11/2018 12:47:21 answering member 4067 label Biography information for Steve Brine
tabling member	478 label Biography information for Lord Field of Birkenhead

990352

registered interest
date	18/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will take steps to allow patients to have access to NHS doctors willing to prescribe cannabis-based medicine in cases where their NHS doctor is unwilling to do so.
tabling member constituency	Cardiff West
tabling member printed	Kevin Brennan
uin	181179
answer	answer is ministerial correction date of answer 23/10/2018 answer text <p>NHS England expects that cannabis-based products for medicinal use should only be prescribed for indications where there is clear evidence of benefit, and in patients where there is a clinical need which cannot be met by a licensed medicine and, where established treatment options have been exhausted.</p><p> </p><p>The decision to prescribe these unlicensed medicines must be made by a specialist doctor – not a general practitioner. These doctors focus on one field of medicine such as neurology or paediatrics and are listed on the General Medical Council’s specialist register. They must make decisions on prescribing cannabis-based products for medicinal use on a case by case basis, and only when the patient has an unmet special clinical need that cannot be met by licensed products. In addition, a specialist on the General Medical Council Register should only prescribe within their own area of practice, and the decision to prescribe should be agreed by the multidisciplinary team.</p><p> </p><p>NHS England, the British Paediatric Neurology Association and the Royal College of Physicians will provide clinical advice to doctors ahead of the law change. The National Institute for Health and Care Excellence has been commissioned to develop more detailed guidelines for clinicians in the longer term.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 23/10/2018 16:43:24 answering member 4067 label Biography information for Steve Brine
tabling member	1400 label Biography information for Kevin Brennan

988889

registered interest
date	16/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether all patients with health conditions previously determined by the Medicines and Healthcare products Regulatory Agency to benefit from the use of cannabis will automatically qualify for prescriptions for medicinal cannabis.
tabling member constituency	Lewisham, Deptford
tabling member printed	Vicky Foxcroft
uin	180265
answer	answer is ministerial correction date of answer 24/10/2018 answer text <p>Subject to Parliamentary approval, from 1 November doctors on the General Medical Council’s specialist register can make the decision to prescribe cannabis-based products for medicinal use where deemed clinically appropriate and in the best interests of patients. Prescribers will need to follow local governance procedures for prescribing unlicensed medicines.</p><p> </p><p>The regulations do not limit the types of conditions that can be considered for treatment and will only be able to be supplied under the prescription or direction of a specialist doctor.</p><p> </p> answering member constituency Winchester answering member printed Steve Brine question first answered 24/10/2018 16:57:55 answering member 4067 label Biography information for Steve Brine
tabling member	4491 label Biography information for Vicky Foxcroft

972291

registered interest
date	12/09/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions he has had with the Home Secretary on the potential effect of legalising cannabis-oil medicines on the availability of cannabis as a gateway drug for social use.
tabling member constituency	Coventry South
tabling member printed	Mr Jim Cunningham
uin	173953
answer	answer is ministerial correction date of answer 09/10/2018 answer text <p>The Secretary of State for Health and Social Care has committed to his officials working closely with the Home Office on legalising the use of cannabis-based medicines, including cannabis-oil. There has not been a meeting between the Secretary of State and the Home Secretary on the potential effect of legalising cannabis-oil medicines on the availability of cannabis as a gateway drug for social use.</p><p> </p><p>An impact assessment is being prepared alongside proposals to consider wider impacts of this policy. There are known harms associated with cannabis use and cannabis remains a controlled drug. The Government has no plans to legalise it for recreational use. As with other medicines in Schedule 2 to the Misuse of Drugs Regulations 2001 (such as morphine and fentanyl), it will continue to be an offence contrary to the Misuse of Drugs Act 1971 to possess a cannabis based medicine without prescription or lawful authority.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 09/10/2018 16:51:24 answering member 4067 label Biography information for Steve Brine
tabling member	308 label Biography information for Mr Jim Cunningham

943843

registered interest
date	18/07/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions he is having with NHS England to ensure that consultants are aware of the licensing process for access to medical cannabis.
tabling member constituency	Gower
tabling member printed	Tonia Antoniazzi
uin	165715
answer	answer is ministerial correction date of answer 23/07/2018 answer text <p>The Department is working with NHS England and equivalents in the devolved administrations to ensure that cannabis-based medicinal products are sourced and supplied where a licence is granted. In the longer-term, prescribing guidance will be developed following any decision to reschedule these products.</p><p> </p><p>Guidance on the licensing process for access to cannabis and cannabis-based medicinal products is available on the Home Office Gov.uk website.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 23/07/2018 15:04:17 answering member 4067 label Biography information for Steve Brine
tabling member	4623 label Biography information for Tonia Antoniazzi

932750

registered interest
date	29/06/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions his Department has had with representatives of the medicinal cannabis industry on the medicinal and therapeutic benefits of (a) cannabis and (b) cannabis-based medicinal products.
tabling member constituency	Brighton, Pavilion
tabling member printed	Caroline Lucas
uin	158986
answer	answer is ministerial correction date of answer 09/07/2018 answer text <p>On 13 June 2018 the Parliamentary Under Secretary of State for Health (Lord O’Shaughnessy) and officials had an introductory meeting with GW Pharmaceuticals, which develops licensed medicines containing ingredients derived from cannabis, during which the benefits of that company’s medicines were discussed.</p><p> </p><p>The Medicines and Healthcare products Regulatory Agency is responsible for the regulation of medicines in the United Kingdom and has provided advice and guidance, on request, to companies developing cannabis-based medicinal products, to support specific medical indications in relation to potential future marketing authorisation applications for new medicines.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 09/07/2018 14:45:09 answering member 4067 label Biography information for Steve Brine
tabling member	3930 label Biography information for Caroline Lucas

869408

registered interest
date	22/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he plans to grant licences for medicinal cannabis products; and if he will make a statement.
tabling member constituency	Gower
tabling member printed	Tonia Antoniazzi
uin	133922
answer	answer is ministerial correction date of answer 29/03/2018 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) is the United Kingdom Agency responsible for the regulation of medicines used in the UK.</p><p> </p><p>The MHRA has not received any marketing authorisation (licence) applications for a medicinal product that contains raw cannabis, for the treatment of any condition in the UK.</p><p> </p><p>If a licence application for a medicinal product containing raw cannabis is received, the MHRA would assess the data submitted to ensure that the product is safe, has efficacy in the purpose claimed for it, is manufactured to the necessary quality standards and that there is a positive balance of benefits over any risks before approval of the licence.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 29/03/2018 11:18:22 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4623 label Biography information for Tonia Antoniazzi